Our previous studies showed that anti-IL-6R antibodies potentially inhibited tumor growth and invasiveness in vitro and in vivo through interfering with IL-6 signaling transduction in IL-6R expressing CRC cell lines, including Erk-1/-2, STAT3 and AKT phosphorylation/activation [15,16]. This evidence concerns the gene MAPK3 and colorectal carcinoma.